Century Therapeutics to Present CNTY-813 Research at Major Diabetes Conferences

Century Therapeutics has been selected to present oral presentations of preclinical data on CNTY-813 at two major conferences in 2026. The presentations will be featured at the European Association for the Study of Diabetes (EASD) 2026 conference and the Breakthrough T1D Clinical & Research Congress 2026.

Selection for oral presentation at these conferences is competitive and reflects that the research meets scientific standards worthy of discussion among diabetes researchers, clinicians, and advocates.

CNTY-813 remains in the preclinical stage, meaning it has been studied in laboratory and animal models but has not yet entered human clinical trials. Preclinical research is an essential early step in drug development, helping scientists understand how a candidate works before testing its safety and effectiveness in people.

Sharing preclinical findings at major conferences allows the scientific community to review the data, ask questions, and build the evidence base that supports the next phases of research.

Origin: Investing News Network (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.